Icatibant Fresenius (Icatibant Acetate)

Icatibant acetate is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor on vascular endothelial cells, it prevents bradykinin‑induced vasodilation and increased vascular permeability, thereby limiting the fluid leakage that causes swelling in HAE attacks.

The dose of Icatibant Fresenius is determined by the prescribing clinician based on the patient’s condition, weight, and severity of the HAE attack. The medication is administered subcutaneously, and the prescriber will provide specific instructions.

Safety of icatibant in pregnancy has not been established, and it is generally avoided unless the potential benefit justifies the risk. Data on use during breastfeeding are also lacking, so a careful risk‑benefit assessment should be performed by the healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other approved HAE therapies include C1‑esterase inhibitor concentrates and kallikrein inhibitors. Icatibant offers a subcutaneous route and rapid onset, making it convenient for self‑administration during acute attacks, while the alternatives are typically intravenous or have different mechanisms.

Icatibant Fresenius must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. If temperature excursions occur, consult the supplier before use.

The medication is supplied as a solution for subcutaneous injection. The prescriber will instruct the patient or caregiver on the injection technique, site selection (typically the abdomen or thigh), and the number of doses required for a given HAE attack.

Serious risks include anaphylaxis, severe hypotension, and unexpected angioedema unrelated to HAE. Patients should be educated to recognize signs of a severe allergic reaction and seek immediate medical attention if they occur.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant acetate or any of the formulation excipients. Caution is also advised for patients with severe renal impairment or those taking ACE inhibitors or neprilysin inhibitors without close monitoring.